Results 31 to 40 of about 3,351 (178)
Frontiers in Medicine, 2022 PurposeTo report a case of primary vitreoretinal lymphoma (PVRL) treated with oral zanubrutinib, who had bilateral intraocular hemorrhage after intravitreal injection of methotrexate (MTX).Case reportA 69-year-old Chinese female presented with vision ...
Xiao Zhang +7 more
doaj +1 more source
Zanubrutinib-induced aseptic meningitis: a case report and literature review
Frontiers in Pharmacology, 2023 Zanubrutinib is a Bruton tyrosine kinase (BTK) inhibitor used in B cell malignancy treatment and is generally well tolerated in most patients. Zanubrutinib-induced aseptic meningitis is currently not reported.
Jinjun Yang +4 more
doaj +1 more source
Pharmacology Research & Perspectives, 2021 Zanubrutinib is a highly selective, potent, orally available, targeted covalent inhibitor (TCI) of Bruton's tyrosine kinase (BTK). This work investigated the in vitro drug metabolism and transport of zanubrutinib, and its potential for clinical drug–drug
Heather Zhang +6 more
doaj +1 more source
Waldenstrom Macroglobulinemia: Clinical Presentation, Diagnosis, and Management in an Elderly Male [PDF]
, 2023 Waldenstrom macroglobulinemia (WM) is a rare lymphoproliferative disease that can have an ambiguous clinical presentation. A key component of the pathophysiology of WM is bone marrow infiltration, which most commonly presents as anemia. Other symptoms of
Daniel, Amy +5 more
core +2 more sources
eJHaem, 2023 Zanubrutinib‐treated and treatment‐naïve patients with chronic lymphocytic leukaemia (CLL) or Waldenstrom's macroglobulinaemia were recruited in this prospective study to comprehensively profile humoral and cellular immune responses to COVID‐19 ...
Thi H. O. Nguyen +19 more
doaj +1 more source
Frontiers in Oncology, 2021 Zanubrutinib is a second-generation Bruton’s tyrosine kinase inhibitor. Its safety and effectiveness in central nervous system (CNS) lymphoma along with its distribution in the brain and ability to cross the blood–brain barrier (BBB) remain unknown. This
Yan Zhang +7 more
doaj +1 more source
Cancer Medicine, 2023 Background We previously reported results of a pooled analysis of two zanubrutinib studies in relapsed or refractory (R/R) MCL showing better survival outcomes when zanubrutinib is used in second‐line versus later‐line. Here, we present an updated pooled
Yuqin Song +21 more
doaj +1 more source
In vitro and in vivo studies of Bruton tyrosine kinase (BTK) mutations & inhibition [PDF]
, 2021 Bruton tyrosine kinase (BTK) is a non-receptor protein kinase that belongs to the TEC family kinases. It plays an important role in the B-cell receptor signaling pathway (BCR) and its pharmacological inhibition has been demonstrated as an effective ...
Estupiñán Velásquez, Hernando Yesid
core +1 more source
BMC Chemistry, 2023 Background This study establishes a UHPLC‒MS/MS method for the detection of zanubrutinib and explores its interaction with fluconazole and isavuconazole in rats. Methods A protein precipitation method using acetonitrile was used to prepare plasma samples
Peng-fei Tang +6 more
doaj +1 more source
Molecules, 2023 Ibrutinib, orelabrutinib, and zanubrutinib are all Bruton’s tyrosine kinase inhibitors, which have greatly improved the treatment of B-cell malignancies. In this study, an LC-MS/MS method was developed and validated for the determination of orelabrutinib,
Lu-Ning Sun +7 more
doaj +1 more source